Peptides for Hair Growth: GHK-Cu and Other Serums Against Minoxidil and Finasteride

No peptide has been shown in a controlled trial to regrow scalp hair the way the two FDA-approved treatments do. GHK-Cu, the copper peptide most often sold for hair, has no trial testing it alone on human scalps; the studies quoted for it used a related peptide in a dish, or GHK without copper mixed with another compound.^[9][10] A few other cosmetic peptides have one small trial each.^[12][13] Minoxidil and finasteride are approved for pattern hair loss, and their own labels exclude the sudden, diffuse shedding that follows fast weight loss on a GLP-1.^[5][6] That shedding, tied to weight reduction on both obesity labels, remits in most cases.^[1][4]

Two kinds of hair loss, and why it matters here

Most hair products, peptide or not, are tested on androgenetic alopecia, the gradual pattern thinning at the crown and temples that runs in families. The hair loss people notice on GLP-1 drugs is usually different. Both obesity labels state that hair loss in their trials was associated with weight reduction.^[1][2] In Zepbound’s weight trials it was reported by 4% to 5% of people on the drug against 1% on placebo, and far more often by women (7.1%) than men (0.5%).^[2] Wegovy’s label reports 3.3% at the 2.4 mg dose against 1% on placebo.^[1] A 2026 meta-analysis of nine trials and studies found about a threefold higher risk of hair loss on GLP-1 drugs than on placebo.^[3]

Shedding after rapid weight loss is generally telogen effluvium: diffuse shedding set off by a physical or emotional stress, including drugs, where treatment starts with identifying and removing the cause.^[4] Acute telogen effluvium lasts under six months and remits in about 95% of cases.^[4] That is a different problem from pattern hair loss, and the timing, the course and when to see a dermatologist are covered in our hair loss article and the hair loss Q&A.

The peptides sold for hair, and their human evidence

GHK-Cu

The lab study usually cited for copper peptides and hair tested AHK-Cu, which has alanine where GHK-Cu has glycine. It lengthened human hair follicles kept alive in culture and helped the cells at their base grow.^[9] That is a reason to run a trial, not evidence of regrowth. The only placebo-controlled scalp trial of GHK used it bound to 5-aminolevulinic acid, without copper: after six months the men using it had more hairs counted than the placebo group, but their hair was no longer and no thicker.^[10] A scalp study that did use a copper tripeptide serum combined it with other active ingredients, ran 15 days, had no comparison group and was co-written by an employee of the product’s maker.^[11] A 2026 review of GHK-Cu across every use called it promising but unproven.^[16] The full record is in GHK-Cu: what the evidence shows.

Other cosmetic peptides

Shiseido scientists tested a five-amino-acid peptide, glycine-proline-isoleucine-glycine-serine, in a lotion on 22 Japanese men with pattern hair loss for four months. Compared with placebo, the share of thick hairs rose and blinded reviewers graded the baldness photos as improved, with no skin side effects reported.^[12] Acetyl tetrapeptide-3 appears in many hair serums, usually with plant extracts. In a 24-week Thai trial, a mix of acetyl tetrapeptide-3, biochanin A and ginseng extracts produced a gain in terminal hairs similar to 3% minoxidil in 32 people, but the trial was small, had no placebo group and did not test the peptide on its own.^[13]

Other peptides marketed for hair, including thymosin beta-4 fragments such as TB-500, have no published human hair trials. Those that are injected are a separate matter, covered in are peptides safe.

What the approved treatments do, per their labels

Two drugs are FDA-approved for pattern hair loss. Their labels set out what they are for and what to expect, and both are narrower than the marketing around hair products in general.

The minoxidil labels tell the user not to use the product if the hair loss is sudden or the cause is unknown.^[6][7] Diffuse shedding a few months into a GLP-1 is sudden and has a likely cause, which is exactly the situation those directions exclude. A dermatologist may still treat telogen effluvium with minoxidil, and reviews list it among the options, but that is a medical decision rather than the use the over-the-counter label covers.^[4]

Why peptide serums can say so little

A product sold with a claim that it will restore hair growth is a drug under federal law, whatever its packaging says, because the claim is about changing how the body works.^[8] Cosmetic hair serums therefore stick to phrases like “fuller-looking” hair. When a peptide serum promises regrowth, it is making a drug claim without drug approval.

Compounded GHK-Cu from pharmacies sits in a different category. In May 2026 FDA put GHK-Cu for routes other than injection back in category 1 of its interim 503A policy, the group of nominated substances it does not intend to act against compounders for using, and plans to take it to its advisory committee before the end of February 2027.^[14] Injected GHK-Cu stays out of category 1, and FDA warns that it may cause immune reactions because of clumping and impurities, with limited human data.^[15] The current status of each peptide is in the peptide status checker.

If you are shedding on a GLP-1

• Expect it to be temporary. The labels tie it to weight reduction, and acute telogen effluvium, shedding that lasts under six months, remits in about 95% of cases.^[1][4] In Zepbound’s trials, no one on the drug stopped treatment because of hair loss.^[2]
• Protein and calories matter more than serums. Severe protein deficiency and calorie restriction are named triggers of telogen effluvium.^[4] The protein calculator gives a daily target, and collagen peptides are a weak way to meet it.
• Patchy loss, scalp pain or shedding past six months needs a dermatologist. Those are not the pattern weight loss usually causes.
• A peptide serum is unlikely to hurt, and unlikely to change the course. No peptide has a trial in shedding after weight loss.